Basic Information

Gene symbol CD19 Synonyms B4, CVID3 Type of gene protein-coding
Description CD19 molecule

Gene symbol CD22 Synonyms SIGLEC-2, SIGLEC2 Type of gene protein-coding
Gene perturbation-related omics dataset PerturbAtlas | PertOrg
Description CD22 molecule

Gene symbol TNFRSF8 Synonyms CD30, D1S166E, Ki-1 Type of gene protein-coding
Description TNF receptor superfamily member 8

GTO ID GTC0378
Trial ID NCT03196830
Disease B-Cell Non-Hodgkin's Lymphoma
Altered gene CD19|CD22|CD30
Therapeutic/Target gene Target gene
TherapyCAR-T cell
Treatment CD19/CD20/CD22 CAR-T cells
Generation2nd
PhasePhase2
Recruitment statusUnknown
TitleCAR-T for R/R B-NHL
Year2017
CountryChina
Company sponsorThe First Affiliated Hospital of Soochow University
Other ID(s)SZ5601
Vector information
Vectorlentivirus
ConstructscFv-4-1BB-CD3ζ

Clinical Result

Cohort1: CD30
Administration route intravenous infusion
Dosage 1E6 cells/kg, 1E7 cells/kg
Donor type Autologous
Pts 12
Age Adult, Older_Adult
Lymph depletion Yes
Outcome 6/12(CR); 5/12(PR)
Adverse reactions 1/12(cytokine release syndrome)
References PMID: 35432352
Cohort2: CD19+CD22
Administration route intravenous infusion
Dosage 3.690E8~3.285E9 cells, day 0, 10%, day 1, 30%, day 2, 60%
Donor type Autologous
Pts 32
Age Adult, Older_Adult
Lymph depletion Yes
Outcome 10/29(CR); 10/29(PD). The progression-free survival (PFS) and overall survival (OS) rates at 12 months were 40.0% and 63.3%, respectively.
Adverse reactions 9/32(cytokine release syndrome); 4/32(neurologic events)
References PMID: 35432352
Cohort3: CD19
Administration route intravenous infusion
Dosage 5E6~10E6 cells/kg
Donor type Autologous
Pts 29
Age Adult, Older_Adult
Lymph depletion Yes
Outcome 12/25(CR)
Adverse reactions 6/29(cytokine release syndrome); 4/29(infection); 3/29(neurotoxicity)
References PMID: 35432352

Relationship Graph

Overview of Knowledge Graph